North, Roivant CEO, Vivek Ramaswarmy, describes his financing model for getting promising drugs through approval in this insightful video at the bottom of the link from wook and yourself.

In the case given, "$5 million upfront, $160 million in milestones if it comes to market, and another 12.5% in royalty fees."

Not unsimilar!

This seems like a deja vu of the Peregrine/AVID R&D deal being run through Oncologie.

Video discusion also covers some other interesting territory.

Roivant raised $1.1 billion from Softbank last year.

Latest PR was new CDMO business from Roivant's Enzyvant.

Interesting.

IMO

sunstar

First we hear the case that anti-PS tech is worthless. But not everybody wants to buy this bridge...So, they try the reverse argument. BP doesn’t want Bavi because it will provide cures for cancer, and BP will put themselves out of business: )

Which is it, no good, or too good?

Truth be told, anti-PS offers much more than superior safety and efficacy for therapeutic treatment of cancer through immunotherapy combinations.

Anti-PS also offers exosome early cancer detection, and PET tumor imaging.

With respect to exosome testing, PPHM has published "Highly Specific PET Imaging of Prostate Tumors in Mice with an Iodine-124-Labeled Antibody Fragment That Targets Phosphatidylserine."

Images of tumor location show clearly in a PET scan. Any metastases should also be evident in a scan.

http://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0084864&type=printable

Exosome test tells doctors/patients that there is a significant quantum of PS-positive exosomes in the patient's system. The next step would be a conformational and locational scan.

Peregrine ran a human trial at Washington University School of Medicine, started June 2012, and closed out on schedule, March 2016. Peregrine has that data.

"Open-label, Single Arm, Tumor Imaging and Dosimetry Study of I-124 PGN650 in Advanced Solid Tumors"

https://clinicaltrials.gov/ct2/show/NCT01632696?term=peregrine+pharmaceuticals&rank=14

The high value of the "Detection of phosphatidylserine-positive exosomes as a diagnostic marker for ovarian malignancies" is the ability to diagnose this ovarian tumor type at an earlier stage than has been previously possible. It should be a real lifesaver for many women in the future of ovarian oncology.

IMO

sunstar

Does it not warm the long investors’ hearts to see the desperate attempts by short operators to collect loose shares by hitting the stop sells of unwary shareholders of CDMO??

So why do they want these CDMO shares so badly??

And why do certain commentators insist that the anti-PS IP is worthless??

The scramble for loose shares lately suggests another story.

Didn’t CEO Lias recently suggest an upside for CDMO shareholders...SOON??

When is SOON??

SOON?

IMO

sunstar

Quotes from CEO Lias on licensing/sale R&D IP.

“Seeking to monetize the R&D assets.”

“There is some residual value we believe.”

“We hope to have news on that front very soon.”

“Obviously that means potential upside for shareholders over the short term.”

IMO

sunstar

The CEO of CDMO has potential income through the sale and licensing of anti-PS diagnostic and therapeutic immuno-oncology IP that could accrue to his company’s CDMO shares. This should be his most efficient income for continuing the planned expansion of the AVID production facilities.

IMO

sunstar

aikifredicist, Thanks, but I could not find this after numerous searches. Could you supply a link to an abstract, or other document. January 18th is a very current publishing date.

IMO

sunstar

Dr. Wolchok’s MSKCC lab produced CAR-T/PS-Targeting data that clearly showed the safety advantage from this immunotherapy combination. This combination is ready for clinical trials combining PS targeting with CAR-T in solid tumor cancers.

It appears that PPHM pre-CDMO pulled back from two separate trials designed to demonstrate PS targeting, bavituximab in combinations with anti-PDx, associated with two companies: AstraZeneca and Merck. Was this an early directional key, pointing to CAR-T?

Data from the pre-clinical and some SUNRISE data showed evidence of increased response rates, efficacy, and safety in the various studies.

There are three main competitors in the CAR-T development race: Novartis, Gilead and Celgene/Juno, moving quickly forward??

If CDMO holds a keystone to much needed safety in the CAR-T development program, we may find that this is the pathway forward.

CAR-T, solid tumors SAFETY...

IMO

sunstar

"...helping non or low responders to pdl and others or limiting toxicty in car-t.... "

Absolutely core central value drivers: responders, efficacy and safety.

Currently two major immunotherapy trajectories in relatively early development: anti-PDx and CAR-T, each with multiple players elbowing and staking first ground.

May various discussions continue. A solution for the right player is the BIG BOX, CDMO and all. As you say, that derisks if really needed?.

IMO

sunstar

"Avid's services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support."

Dr. Garnick could have been contracted to do AVID's regulatory work.

The photo shows him working with Joe Shan, back in the day. Maybe they'll update the photo for you.

IMO

sunstar

golfho, thanks for your company BOD email address. I sent this through today:

Sale and/or Licensing of Peregrine R&D IP

Dr. Carleone, and fellow Peregrine/AVID board members:

My name is xx. I first invested in Peregrine in 2005: I remain invested today.

My purpose in this communication is to make you aware of my concern that shareholders receive full and fair value from the current process of selling or licensing Peregrine IP.

There have been many bavituximab clinical trials, including phase II and phase III registrational trials. In some of the trials there were obvious over-performing anomalous results involving the control arms. One incident was brought to trial where judgement required the contractor, CSM of Fargo, ND to pay a nominal contract penalty to Peregrine. With a normal control arm that 2012 trial could have received an FDA Accelerated Approval. The bavituximab treatment arm more than doubled the standard of care that was tampered with by CSM. In all of these trials Peregrine had strongly performing treatment arms. I find it interesting that the treatment arms remained uncontaminated. Strong bavituximab data were collected without the possibility of an FDA approval. It seems well beyond coincidence these control arms were so irregular while the main active bavituximab arms were not diminished, and performed as expected. Was a party watching the bavituximab performance while assuring that no FDA approvals were possible?

Bavituximab has shown itself to be an active efficacious and safe immunotherapy and immuno-modulator. Pre-clinical and clinical data are available to you at the company for your examination.

My concern is that Peregrine investors see the R&D IP fully and fairly valued through the process, recently announced by Peregrine, to sell and/or license the R&D IP, and that it is accomplished through a widely based and well announced competitive bidding process.

Thank you for taking the time to hear my concerns. You may contact me at:xxxx

sunstar

"in humans?" YES! Peregrine has clinical data now for bavituximab in combination immunotherapy.

The first immunotherapy combination human trial was bavi with Yervoy. Peregrine has these data available for negotiating a sale or licensing of the IP, along with immuno combinations that occurred post SUNRISE. Many long investors know these facts. It may be that some aren't paying close attention to what has transpired in the clinic.

CAR-T anti-PS combination preclinical data has been published by Peregrine with the Wolchok MSK lab. One must keep one's ear to the ground...if one still has ears!

north40000, who keeps an ear to the ground, has had some communications with Dr. Wolchok related to a human combination trial with bavi and CAR-T. waiting for a go signal. This remains speculative, but if a CAR-T company is fingering the goods, they would want to run that trial, and others as well.

IMO

sunstar

CAR-T cost per patient should decrease when safety increases the footprint of patients who can be safely treated. That efficiency of a larger treatable patient population also goes for other immunotherapies, like the anti-PDxx variety.

Bavituximab provides that safety. Dr. Brekken of UTSW clearly stated that he saw a 200% to 300% increased response rate footprint where bavi was combined with other immunotherapies. That means increased efficacy and safety.

That's science, that's a fact.

IMO

sunstar

TOG, We are in full agreement on YearEnd. That's an important timing marker for PPHM holders.

Good luck to you, and all investors.

IMO

sunstar

Interesting, Joe Shan was needed to the end of the month. Joe is Vice President, Clinical & Regulatory Affairs. Joe has been with Peregrine since 2000, and has deep technical knowledge in the clinic and in regulation.

Dr. Shelly Fussey, Vice President, Intellectual Property also remains on board. IP

"Dr. Fussey plays a key role in our U.S. and international patenting, patent analysis and patent defense. Dr. Fussey's expertise includes patent strategy for technologies developed both in-house and in-licensed from universities. She has broad experience in intellectual property consulting for areas including cancer treatment, immunology, and antiviral technology, as well as other areas central to pharmaceutical and biotechnology drug development."

Sard Verbinnen & Co | Strategic Communications is also working with Peregrine.

CEO King, and others have made it clear that Peregrine is in the process selling and licensing the R&D.

That's a good start at: HEADS UP!!

Good luck to long investors in PPHM.

Wishing you and yours, good health, joy, and a prosperous New Year.

IMO

sunstar

We're trading mid range February 17, 2017 prices. It seems to be a preferred range for accumulation. I believe that was about when Ronin was establishing their position.

This volume is lower, but it seems like more accumulation of PPHM.

IMO

sunstar

Thanks Jake, Could be a major timing consideration. Revelation of some M&A agreements could very well be tied to the effective tax date for repatriation of offshore cash. We see that GILD (an interesting example) is flush with offshore cash of approximately $32 billion.

IMO

sunstar

4Our, that's an excellent point. AVID's fully experienced in all things PS related. It makes so much sense that this be a whole package, or...

The Whole Enchilada!!

IMO

sunstar

Geo, shorts are players. They play to win by driving the price down then loading up at prices that offer expanded leverage.

You know what they say: BUY LOW!!

IMO

sunstar

Consider the possibility: AVID goes with the IP.

AVID is a powerful and expanding CDMO that would be a valuable asset to any pharma interested in acquiring anti-PS tech, mAbs, Bavituximab/BetaBodies, exosome diagnostics, biomarker tech, imaging tech.

Also CAR T cell processing will be of major an growing importance as new FDA approvals, especially in the solid cancer indications, come online.

Here is a current commercial description of AVID.

“Avid Bioservices, a full-service CDMO, provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With over 20 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, including 12 years of commercial manufacturing for products sold in 18 countries, Avid's services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, lot release and stability testing, regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development, qualification/validation, process and product characterization.”

https://www.contractpharma.com/csd/profile/avid-bioservices-inc-/

Dr. Lias:

“We are in active discussions to divest the legacy Peregrine R & D assets, and have taken actions to formally wind down all formal R & D activities not required to affect the transition." 

“Lastly We are taking steps to transition Peregrine and AVID into a single entity, and will change the name of the company into AVID Bioservices Inc.   

“Through this process there will be no change to the company shares outstanding or the shares held by individual shareholders.” 

I see nothing in the statement above that excludes the possibility that IF THE DEAL IS ADEQUATE/SUBSTANTIAL, AVID could be included.

Who, including the BOD, is not going to sell their shares if the deal is RIGHT??

In a recent interview both SK and Lias have acknowledged that possibility.

https://www.outsourcing-pharma.com/Article/2017/11/15/Peregrine-transitioning-to-pure-play-CDMO?utm_source=copyright&utm_medium=OnSite&utm_campaign=copyright

IMO

sunstar

Cell Design! AVID, this year added a new arm for "cell design". So AVID itself may become a target along with Peregrine's anti-PS technologies, mAbs etc.

CAR T should definitely be on our radar, as well as the anti-PDxx immunotherapy combinations.

Safety and increased treatment footprints are strong factors for immunotherapy BPs.

IMO

sunstar

"Sard Verbinnen used in the Gilead/Pharmasset deal.

Nice find bio. In reading the link we see that Sard Verbinnen represented the company being acquired, Pharmasset.

The 2011 Gilead/Pharmasset deal caught pharma investors' attention because of the magnitude of the offering ($11 billion) to a small bio without any FDA approved drugs.

http://investors.gilead.com/phoenix.zhtml?ID=1632335&c=69964&p=irol-newsArticle

Now Sard Verbinnen is representing Peregrine.

IMO, Expect full value.

"Transaction Communications"

https://www.sardverb.com

A GLOBAL Company

"...offers transaction communications services on a range of equity and debt transactions, such as negotiated mergers and acquisitions,"

https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=1565263

IMO

sunstar

What is possible with an acquisition?

Gilead (GILD) acquired Pharmasset in November 2011 for a HepC drug that was not FDA approved, and still in phase 2 trial stage.

GILD paid $11 billion for that phase 2 drug.

GILD has profited hugely since, curing HepC patients over the following years.

Unlike the multitude of cancer cases and indications that occur endlessly in various patient populations, the virus infected HepC patients tend to run out as treatments cure the disease in various populations, and GILD’s HepC revenues have been slowly decreasing.

After acquiring the Pharmasset drug in 2011, GILD went from ~ $20 pps to over $100 pps in just three years after the acquisition.

What is possible with an acquisition?

What can PPHM’s anti-PS mAbs do for cutting edge cancer therapy?

PPHM’s anti-PS mAbs when combined with anti-PD immunotherapies have been shown to substantially increase efficacy footprints and patient safety.

Dr. Rolf Brekken claims increased response rates of 200% to 300% when anti-PS is combined with anti-PDs.

PPHM’s anti-PS, Bavituximab, has also demonstrated excellent safety after treating over 1000 patients.

What would a small immunotherapy deal for just anti-PS mAbs, like Bavituximab and maybe betabodies look like in pps?

~$22 pps currently represents $1 billion @PPHM. $11billion = $242 pps for PPHM shares.

Calculate that.

GILD has again, in August 2017, paid out nearly $12 billion for Kite Pharma and a leading edge cancer therapy, CAR T.

CAR T therapies are powerful cancer fighters, sometimes too powerful, killing an unacceptable number of patients. We know from Memorial Sloan Kettering data that PPHM’s anti-PS offers the crucial increased safety for CAR T therapy when combined with anti-PS mAbs for treating cancer.

GILD now sits at a market cap of around $98 billion.

The largest BP now developing CAR T is Novartis (NVS) with a market cap of $201 billion, double the size of GILD.

All the CAR T companies are acutely aware of the CAR T safety issues and challenge.

Interestingly, NVS also has a a clinical research collaboration with Bristol-Myers Squibb, to investigate Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab), (anti-PD-1) and (CTLA-4) immunotherapies.

PPHM has data that show that anti-PS in combination with the above immunotherapies can substantially increase treatment footprints, and very importantly, the crucial safety needed for cancer patients.

Peregrine would be negotiating for full value for Bavituximab and possibly betabodies (IP), with respect to wider footprints and the increased safety needed by competing immunotherapy companies, and their emerging immunotherapies.

IMO this will mean nothing less for Peregrine than $12 billion to $15 billion.

Calculate this!

Then there is also the PPHM exosome diagnostics. This diagnostic market is massive, and might just double, or better the anti-PS IP immunotherapy market value.

Calculate double!

IMO

sunstar

Hey Swing, The figures are projections. They did seem to cross reference with other projectors.

With the exosome screenings, it may be that most patients can afford these lab tests without insurance paying. I don't know. This early screening may actually save long term costs for insurers. If it is relatively low cost and/or partially subsidized, the numbers may be ballpark. We have to remember these are GLOBAL (billion(s) patient(s) projections.

IMO

sunstar

Global Cancer Diagnostics Market $232.7 Billion by 2025

Separate from cancer therapy this market projection is the target for PPHM exosomes and, likely, PGN650 tumor imaging.

Amazing! This is an even larger market than cancer therapy.

I see ‘ASTRONOMICAL’ exosome leverage for PPHM.

https://www.reuters.com/brandfeatures/venture-capital/article?id=4899

IMO

sunstar

“Global cancer drug spending to exceed $150 billion by 2020: IMS report”

“Worldwide spending on cancer medicines will exceed $150 billion by 2020, driven by the emergence of expensive new therapies that help the immune system to attack tumors, according to a global oncology report released by IMS.”

https://www.reuters.com/article/us-health-cancer-spending/global-cancer-drug-spending-to-exceed-150-billion-by-2020-ims-report-idUSKCN0YO0BQ

IMO

sunstar

Many may appreciate that sleepiness.

IMO

sunstar

The wise men, like Joe Shan, might now be able to spend their big salary savings on PPHM paper!?!

IMO

sunstar

Takes pressure off PPHM and strengthens our negotiators.

IMO

sunstar

Interesting graph: Keytruda vs. Opdivo sales 1Q15-3Q17

These competitors, Merck and BMY, need to differentiate in this new and fast growing immunotherapy cancer marketplace. Not only do they have to outperform each other, they will be soon in direct competition with the powerful CAR T immuno-therapies.

Peregrine’s anti-PS mAbs have been shown to increase the efficacy footprint for these anti-PD-1 mAbs. Peregrine’s anti-PS mAbs have also demonstrated a high degree of safety in combinations with anti-PD-1 and with CAR T.

Graph:

http://www.loncarblog.com/keytruda-vs-opdivo-sales

IMO

sunstar

Sard Verbinnen & Co. now Peregrine’s Media Relations. Offers a full suite of services, including,

Transaction Communications:

“...mergers and acquisitions, hostile offers and defenses, proxy contests, shareholder activism,..”

SVC is a major. Number one in 2016 advising on $453 Billion in transactions.

https://www.sardverb.com/wp-content/uploads/2017/07/Global_and_regional_league_tables_for_H1_2017_PR_advisors.pdf

Peregrine (SVC) San Francisco contact is John Christiansen.

“John Christiansen is a Managing Director in San Francisco and Co-Head of the firm’s West Coast offices. He advises a wide range of clients on strategic communications, including contested and friendly M&A transactions, corporate positioning, crisis situations, proxy contests, management changes and IPOs, as well as ongoing media relations and investor relations programs.”

John Christiansen:

“Prior to Cowen, John spent over ten years at Morgan Stanley in Investment Banking and Institutional Equities. As a member of Morgan Stanley’s Technology Investment Banking Group in Silicon Valley, he was involved in 49 financing and M&A transactions. He also helped establish the firm’s Institutional Corporate Marketing group, which worked with companies on their investor marketing activities.

John holds a B.A. magna cum laude with high honors from Dartmouth College and a Master of Public Policy degree from Harvard University.”

SVC main website:

https://www.sardverb.com

IMO

sunstar

PPHM announced it's it will licence/sell anti-PS IP. Joe Shan, is an insider who would not normally be able to buy during this negotiating process, except that he is leaving to pursue his career. So he can use his employee stock ownership plan (ESOP). Joe's buying!! A great sign for long Investors, IMO. Bamford is able to buy because he is transitioning in, and is not yet an insider. Note that other current insiders are not, at this time, buying during the negotiation process. They would be under restrictions.

"The company is pursuing to license or sell its proprietary R&D assets, including its lead immunotherapy candidate, bavituximab, which is currently being evaluated in clinical trials in combination with immune stimulating therapies for the treatment of various cancers."

http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=1048430

IMO

sunstar

north, notice that the third generation CAR therapy was using ox40 as a modulator. Yes, the MSK lab demonstrated that PPHM's anti-PS mAb provided much better safety than the ox40 modulator in CAR-T therapy for melanoma.


Peregrine Poster:

http://www.peregrineinc.com/images/stories/pdfs/aacr2017hirschhorn.pdf

IMO

sunstar

Novartis holding 33%/Roche, developing CAR-T liquid, plays coy with respect to acquisitions, large and small.

CAR-T SOLID is happening now at U Penn and several other universities, in phase 1&2 sponsored trials, in various sold tumors. PPHM anti-PS has also shown it with excellent safety through MSK under Dr. Wolchok.

Many other CAR-T phase 1&2 clinical trials for solid tumors are now occurring in China. This tech is really on the move around the world.

Here is coverage. Check Table 2 at the bottom of the page.

https://jhoonline.biomedcentral.com/articles/10.1186/s13045-017-0444-9

Companies with anti-PDs and CTLA-4 will be of interest: BMY and AZN.

Maybe Novartis will wait on these companies making their moves, then do a 'Two Step', and sweep up the works??

IMO

sunstar

"Wow brilliant. I like what you wrote" laVieEnRose and I are in agreement, These two posts, PART I and PART II cover much of the important information that the long investors need to know.

A MUST READ!

Thanks for your efforts.

IMO sunstar

Front-line lung cancer a [$20 billion annual sales]. [$20 BILLION, EACH YEAR, ONE INDICTION]: Thank you, hutschi, for this Roche coverage. All the major BP's will compete vigorously to somehow dominate this most important indication and market, plus the many other indications and markets.

PPHM's anti-PS, Bavituximab, could end up being critical in helping to establish the immuno-oncology dominance by providing enhanced immune efficacy and safety across this space for the various anti-PD IOs through to the CAR T technologies.

"Lung cancer is by far the biggest oncology market and first-line treatment provides access to the most patients, opening up potential annual sales forecast by some analysts at $20 billion."

IMO

sunstar

PPHM up 97.32% over 52 weeks. Institutional holdings and large shareholder positions have increased substantially.

Peregrine holds valuable assets in AVID and IP related to anti-PS technology.

CEO King has stated clearly that PPHM is in the process of licensing or selling the IP portion of the company.

“The company is pursuing to license or sell its proprietary R&D assets, including its lead immunotherapy candidate, bavituximab, which is currently being evaluated in clinical trials in combination with immune stimulating therapies for the treatment of various cancers.”

I believe AVID may also be on the block. CLEAN HOUSE?? BIG DEAL!! ??

AVID M&A mentioned separately by Lias and King, described as “a potential”, and “very hot” referencing the CDMO space.

https://www.outsourcing-pharma.com/Article/2017/11/15/Peregrine-transitioning-to-pure-play-CDMO?utm_source=copyright&utm_medium=OnSite&utm_campaign=copyright

It’s November 18th and the next scheduled event is the ASM on January 18th. Other interesting events could break out as PR news in the next two months. “One never knows. Do one?”

Not betting against “the Microsoft of Biotechnology!”

IMO

sunstar

AVID M&A mentioned separately by Lias and King, described as “a potential”, and “very hot” referencing the CDMO space.

https://www.outsourcing-pharma.com/Article/2017/11/15/Peregrine-transitioning-to-pure-play-CDMO?utm_source=copyright&utm_medium=OnSite&utm_campaign=copyright

Hutschi, Thanks for your excellent finds.

(If) both AVID and PPHM R&D, IP, etc. are in transition by way of M&A...

100% of PPHM will sit in shares held.

IMO

sunstar

Bavituximab increases anti-PDx footprints 200%-300%, and increases the safety along with efficacy.

Long PPHM investors well know also, that the Memorial Sloan Kettering lab has reported that CAR-T therapies also benefit from needed added safety when in combination with the anti-PS immunotherapy that is offered with Bavituximab.

By adding safety to these other immunotherapies, anti-PS in combination allows for the safer treatment of many more patients that would otherwise not be able to be safely and efficaciously treated by these emerging anti-PD and CAR T immunotherapies.

IMO

sunstar

CDMO should, among other things, mean biosimilars development and manufacturing. We are now well into the age of biosimilar medicines. More and more they will be going off patent. AVID is growing fast, and is now a full fledged CDMO.

IMO

sunstar

After all else has failed for (DLBCL) diffuse large B-cell lymphoma, then and only then may GILD’s CAR T be used for treatment.

Why? because CAR T has a BIG safety problem:

IMPORTANT SAFETY INFORMATION

BOXED WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGIC TOXICITIES

Cytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred in patients receiving Yescarta. Do not administer Yescarta to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids.

Neurologic toxicities, including fatal or life-threatening reactions, occurred in patients receiving Yescarta, including concurrently with CRS or after CRS resolution. Monitor for neurologic toxicities after treatment with Yescarta. Provide supportive care and/or corticosteroids as needed.

Yescarta is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Yescarta REMS.

Cytokine Release Syndrome (CRS)


Gilead’s “Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy”

http://www.gilead.com/news/press-releases/2017/10/kites-yescarta-axicabtagene-ciloleucel-becomes-first-car-t-therapy-approved-by-the-fda-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-large-bcell-lymphoma-after-two-or-more-lines-of-systemic-therapy

CAR T therapies need a major assist with safety.

Long investors in Peregrine who follow Peregrine’s anti-PS development program are aware of the excellent safety data resulting when CAR T is combined with anti-PS mAbs.

“Targeting phosphatidylserine in combination with adoptive T cell transfer eliminates advanced tumors without off-target toxicities in a melanoma preclinical model”

Memorial Sloan Kettering/Peregrine Pharmaceuticals collaboration.

http://www.peregrineinc.com/images/stories/pdfs/aacr2017hirschhorn.pdf

When CAR T companies solve their safety issues, they should quickly move to an expanded market of front line treatments of solid and liquid cancers. That would be a move from being a $billion dollar treatment in annual revenues to multi $billions of dollars annually.

Peregrine owns the anti-PS IP that solves CAR T safety issues.

How big is the market??

I have access to a long list of cancer indications that expresses the expanse of the potential oncology market that needs safe and efficacious solutions.

IMO

sunstar